Phase I study of intravenous ASA404 (vadimezan) administered in combination with paclitaxel and carboplatin in Japanese patients with non‐small cell lung cancer
暂无分享,去创建一个
Y. Horio | M. Shi | H. Tanii | Ken Kobayashi | M. Nishio | N. Yamamoto | T. Hida | T. Hirashima | M. Tamiya | T. Horai
[1] L. Freitag,et al. Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800mg/m(2) combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. , 2009, Lung cancer.
[2] J. Lafitte,et al. Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer , 2008, British Journal of Cancer.
[3] Jayne Tierney,et al. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] M. Michaelson,et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] H. Tsukuma,et al. Trends in Lung Cancer Incidence by Histological Type in Osaka, Japan , 2008, Japanese journal of clinical oncology.
[6] M. McKeage,et al. Comparison of safety and efficacy between squamous and non-squamous non-small cell lung cancer (NSCLC) patients in phase II studies of DMXAA (ASA404) , 2008 .
[7] R. Radinsky,et al. Effect of AMG 479 on anti-tumor effects of gemcitabine and erlotinib against pancreatic carcinoma xenograft models , 2008 .
[8] John Smeraglia,et al. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins , 2007, Journal of Translational Medicine.
[9] D. Harlan,et al. Pancreatic islet cell therapy for type I diabetes: understanding the effects of glucose stimulation on islets in order to produce better islets for transplantation , 2007, Journal of Translational Medicine.
[10] J. Ferlay,et al. Estimates of the cancer incidence and mortality in Europe in 2006. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[11] Edward L Spitznagel,et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] M. Ravic,et al. 5,6-Dimethylxanthenone-4-Acetic Acid in the Treatment of Refractory Tumors: a Phase I Safety Study of a Vascular Disrupting Agent , 2006, Clinical Cancer Research.
[13] Christian Ludwig,et al. Rat tumor response to the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid as measured by dynamic contrast-enhanced magnetic resonance imaging, plasma 5-hydroxyindoleacetic acid levels, and tumor necrosis. , 2006, Neoplasia.
[14] Chryso Kanthou,et al. Disrupting tumour blood vessels , 2005, Nature Reviews Cancer.
[15] J. Ferlay,et al. Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.
[16] B. Baguley,et al. Relationship between tumour endothelial cell apoptosis and tumour blood flow shutdown following treatment with the antivascular agent DMXAA in mice , 2004, British Journal of Cancer.
[17] L. Gumbrell,et al. Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent , 2003, British Journal of Cancer.
[18] G. Rustin,et al. 5,6-Dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study , 2003, British Journal of Cancer.
[19] Alan D. Lopez,et al. Global and regional estimates of cancer mortality and incidence by site: II. results for the global burden of disease 2000 , 2002, BMC Cancer.
[20] B. Baguley,et al. DMXAA: an antivascular agent with multiple host responses. , 2002, International journal of radiation oncology, biology, physics.
[21] W. Wilson,et al. Potential of DMXAA combination therapy for solid tumors , 2002, Expert review of anticancer therapy.
[22] J. Verdebout,et al. The role of microvessel density on the survival of patients with lung cancer: a systematic review of the literature with meta-analysis , 2002, British Journal of Cancer.
[23] C. Kieda,et al. Induction of endothelial cell apoptosis by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid , 2002, British Journal of Cancer.
[24] A. Rojiani,et al. Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy , 2002, International journal of cancer.
[25] T. Kumabe,et al. Intraoperative radiation therapy (IORT) for previously untreated malignant gliomas , 2002, BMC Cancer.
[26] K. Sugimachi,et al. High vascularity in the peripheral region of non-small cell lung cancer tissue is associated with tumor progression. , 2001, Lung cancer.
[27] K. O'Byrne,et al. Prognostic significance of platelet and microvessel counts in operable non-small cell lung cancer. , 2000, Lung cancer.
[28] J. Sedgwick,et al. Induction of intratumoral tumor necrosis factor (TNF) synthesis and hemorrhagic necrosis by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF knockout mice. , 1999, Cancer research.
[29] C. Angeletti,et al. Angiogenesis as a prognostic indicator of survival in non-small-cell lung carcinoma: a prospective study. , 1997, Journal of the National Cancer Institute.
[30] J. Folkman. What is the evidence that tumors are angiogenesis dependent? , 1990, Journal of the National Cancer Institute.
[31] A. Jemal,et al. Global Cancer Statistics , 2011 .
[32] J. Vansteenkiste,et al. First-line treatment patterns in advanced NSCLC in western Europe (EU), the United States, and Japan including a comparative analysis of younger versus elderly patients. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] L. Kèlland,et al. Targeting Established Tumor Vasculature: A Novel Approach to Cancer Treatment , 2005 .
[34] W. Wilson,et al. Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) , 2002, Cancer Chemotherapy and Pharmacology.
[35] A. Jemal,et al. Global cancer statistics , 2011, CA: a cancer journal for clinicians.
[36] M A Konerding,et al. Microvascular corrosion casting in the study of tumor vascularity: a review. , 1995, Scanning microscopy.
[37] J. Gavin,et al. Correlation between immune and vascular activities of xanthenone acetic acid antitumor agents. , 1994, Oncology research.